221 related articles for article (PubMed ID: 9918217)
1. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model.
O'Leary JJ; Shapiro RL; Ren CJ; Chuang N; Cohen HW; Potmesil M
Clin Cancer Res; 1999 Jan; 5(1):181-7. PubMed ID: 9918217
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic potential of camptothecin and topotecan.
Clements MK; Jones CB; Cumming M; Daoud SS
Cancer Chemother Pharmacol; 1999; 44(5):411-6. PubMed ID: 10501915
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
Houghton PJ; Cheshire PJ; Hallman JC; Bissery MC; Mathieu-Boué A; Houghton JA
Cancer Res; 1993 Jun; 53(12):2823-9. PubMed ID: 8504425
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts.
Petrangolini G; Pratesi G; De Cesare M; Supino R; Pisano C; Marcellini M; Giordano V; Laccabue D; Lanzi C; Zunino F
Mol Cancer Res; 2003 Oct; 1(12):863-70. PubMed ID: 14573787
[TBL] [Abstract][Full Text] [Related]
5. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
Allegrini G; Goulette FA; Darnowski JW; Calabresi P
Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
[TBL] [Abstract][Full Text] [Related]
6. Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.
Pastorino F; Loi M; Sapra P; Becherini P; Cilli M; Emionite L; Ribatti D; Greenberger LM; Horak ID; Ponzoni M
Clin Cancer Res; 2010 Oct; 16(19):4809-21. PubMed ID: 20702613
[TBL] [Abstract][Full Text] [Related]
7. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
Pollack IF; Erff M; Bom D; Burke TG; Strode JT; Curran DP
Cancer Res; 1999 Oct; 59(19):4898-905. PubMed ID: 10519402
[TBL] [Abstract][Full Text] [Related]
8. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
[TBL] [Abstract][Full Text] [Related]
9. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Fontanini G; Cuccato S; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2001 May; 7(5):1459-65. PubMed ID: 11350918
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
Burris HA; Fields SM
Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144
[TBL] [Abstract][Full Text] [Related]
12. The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH.
Flowers JL; Hoffman RM; Driscoll TA; Wall ME; Wani MC; Manikumar G; Friedman HS; Dewhirst M; Colvin OM; Adams DJ
Cancer Chemother Pharmacol; 2003 Sep; 52(3):253-61. PubMed ID: 12783198
[TBL] [Abstract][Full Text] [Related]
13. The camptothecin derivative CPT-11 inhibits angiogenesis in a dual-color imageable orthotopic metastatic nude mouse model of human colon cancer.
Ji Y; Hayashi K; Amoh Y; Tsuji K; Yamauchi K; Yamamoto N; Tsuchiya H; Tomita K; Bouvet M; Hoffman RM
Anticancer Res; 2007; 27(2):713-8. PubMed ID: 17465193
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
Houghton PJ; Cheshire PJ; Hallman JD; Lutz L; Friedman HS; Danks MK; Houghton JA
Cancer Chemother Pharmacol; 1995; 36(5):393-403. PubMed ID: 7634381
[TBL] [Abstract][Full Text] [Related]
15. The current status of camptothecin analogues as antitumor agents.
Slichenmyer WJ; Rowinsky EK; Donehower RC; Kaufmann SH
J Natl Cancer Inst; 1993 Feb; 85(4):271-91. PubMed ID: 8381186
[TBL] [Abstract][Full Text] [Related]
16. Camptothecin analogues with enhanced antitumor activity at acidic pH.
Adams DJ; Dewhirst MW; Flowers JL; Gamcsik MP; Colvin OM; Manikumar G; Wani MC; Wall ME
Cancer Chemother Pharmacol; 2000; 46(4):263-71. PubMed ID: 11052623
[TBL] [Abstract][Full Text] [Related]
17. Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin.
De Cesare M; Pratesi G; Perego P; Carenini N; Tinelli S; Merlini L; Penco S; Pisano C; Bucci F; Vesci L; Pace S; Capocasa F; Carminati P; Zunino F
Cancer Res; 2001 Oct; 61(19):7189-95. PubMed ID: 11585754
[TBL] [Abstract][Full Text] [Related]
18. Irsogladine maleate inhibits angiogenesis in wild-type and plasminogen activator-deficient mice.
Ren CJ; Ueda F; Roses DF; Harris MN; Mignatti P; Rifkin DB; Shapiro RL
J Surg Res; 1998 Jul; 77(2):126-31. PubMed ID: 9733598
[TBL] [Abstract][Full Text] [Related]
19. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH.
Gabr A; Kuin A; Aalders M; El-Gawly H; Smets LA
Cancer Res; 1997 Nov; 57(21):4811-6. PubMed ID: 9354443
[TBL] [Abstract][Full Text] [Related]
20. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
Kumar S; Mokhtari RB; Sheikh R; Wu B; Zhang L; Xu P; Man S; Oliveira ID; Yeger H; Kerbel RS; Baruchel S
Clin Cancer Res; 2011 Sep; 17(17):5656-67. PubMed ID: 21788355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
